Metabolic glycoengineered exosomes enable in situ PD-L1-Fc assembly for targeted immunotherapy in ulcerative colitis

What To Know

The study reports a two‑step in vivo targeting method: orally delivered azide‑modified exosomes accumulate in inflamed colonic segments; a separately administered DBCO‑modified PD‑L1‑Fc then clicks to the exosomes in situ, producing PD‑L1‑Fc–decorated exosomes at the lesion.

In the authors’ murine colitis model, this approach was associated with improved clinical and histological metrics, shifts in local immune cell populations (including more regulatory T cells and M2 macrophages), increased IL‑10, reduced proinflammatory cytokines, and changes in the gut microbiota toward taxa linked with mucus protection and short‑chain fatty acid production.

The work is preclinical and presented as a proof‑of‑concept in mice using engineered exosomes and bioorthogonal chemistry. The paper is published in the Journal of Nanobiotechnology and reports experimental outcomes in an animal model; it does not provide human clinical data.